the aid library

LIST OPTIONS

Filter

9440

Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease
recommended

World Health Organization WHO (2020) C1

To save the lives of mothers and their babies, mitigate complications, and limit the spread of disease, it is critical that recommendations are made on the prevention, treatment, and surveillance of women who are exposed to EVD, acquire EVD during pregnancy or breastfeeding, or survive EVD with ongo... more

Download (427)

View PDF (343)

Considerations for developing a national genomic surveillance strategy or action plan for pathogens with pandemic and epidemic potential

World Health Organization WHO (2023) C_WHO

Pathogen genomic surveillance has become a priority for public health systems in recent years. Genomic sequencing is increasingly being used to characterize pathogens and monitor important public health priorities (e.g. poliovirus, influenza virus, Mycobacterium tuberculosis and Vibrio cholerae, ant... more

Download (265)

View PDF (581)

Recommendations for investigating contacts of persons with infectious Tuberculosis in low- and middle-income countries

World Health Organization (2012) C_WHO

WHO/HTM/TB/2012.9

Download (222)

View PDF (283)

Vaccine crisis communication manual: step-by-step guidance for national immunization programmes

World Health Organization WHO, Regional Office of Europe (2022) CC

Download (315)

View PDF (482)

HEARTS. Tool for the development of a consensus protocol for treatment of hypertension

World Health Organization WHO, et al. (2018) C_WHO

Technical package for cardiovascular disease management in primary health care.

Download (312)

View PDF (320)

Ten Immediate WASH Actions in Healthcare Facilities for COVID-19 Response
recommended

World Health Organization WHO (2020) C_WHO

This page describes ten immediate water, sanitation and hygiene (WASH) actions that low-resource healthcare facilities can undertake with limited budget in the near-term (0-3 months) to prepare for and address COVID-19. On the second page, WHO and UNICEF have provided input on how to best adapt thei... more

Download (197)

View PDF (462)

Supporting improvement of infection prevention and control programmes at national and facility levels in Ukraine during the COVID-19 pandemic in 2020: report

World Health Organization WHO, Regional Office of Europe (2021) CC

This report offers a summary of the provided support and recommendations on priority activities for IPC improvement at national and facility levels. The COVID-19 pandemic spotlighted areas for improvement in the IPC programme at national and facility levels. Improvements in the IPC programme were ac... more

Download (229)

View PDF (517)

Risk communication and community engagement: a compendium of case studies in times of COVID-19

World Health Organization WHO, Regional Office of Europe (2022) C_WHO

This collection of case studies on risk communication and community engagement (‎RCCE)‎ from 18 different country/area level public health partners in the WHO European Region provides evidence of numerous results achieved and lessons learned since the start of the COVID-19 pandemic. RCCE has not... more

Download (233)

View PDF (573)

Guideline on management of pneumonia and diarrhoea in children up to 10 years of age

World Health Organization WHO (2024) C_WHO

Pneumonia and diarrhoea account for 23% of under-five mortality and were responsible for an estimated 1.17 million deaths in children under five globally. Furthermore, pneumonia and diarrhoea were responsible for 18% of mortality in children 5–9 years of age, resulting in an estimated 86 000 preve... more

Download (259)

View PDF (259)

Facilitator’s guide: communicating with patients about COVID-19 vaccination

World Health Organization WHO, Regional Office of Europe (2021) C_WHO

Download (369)

View PDF (383)

Preventing and responding to sexual misconduct WHO’s three-year strategy 2023-2025

World Health Organisation (WHO) (2023) C_WHO

Sexual exploitation, sexual abuse and sexual harassment (SEAH) violate the rights and wellbeing of the people we serve and the people with whom we serve. Such behaviours are directly in opposition to WHO’s values and our abiding responsibility to do no harm. WHO uses the umbrella term “sexual mi... more

Download (156)

View PDF (179)

Polio transition strategic framework: monitoring and evaluation

World Health Organization WHO (2024) C_WHO

The Polio Transition1 Monitoring and Evaluation (M&E) Framework was designed to monitor progress towards achieving the strategic and operational outcomes of the post-2023 Strategic Action Plan on Polio Transition (2018– 2023), as outlined in the Global Vision to use polio investments to build st... more

Download (276)

View PDF (378)

Tests diagnostiques pour le dépistage du SARS-CoV-2 : orientations provisoires, 11 septembre 2020

World Health Organization WHO (2020) C_WHO

Available in Arabic, Chinese, English, French, Portuguese, Russian and Spanish https://apps.who.int/iris/handle/10665/334254

Download (249)

View PDF (215)

Policy brief: analysing the effectiveness of targeting under AB PM-JAY in India

World Health Organisation (WHO) (2022) C_WHO

This report presents key findings from a study on ‘assessing the effectiveness of targeting mechanisms under PMJAY’. It provides a detailed analysis of potential inclusion and exclusion errors in two select states in India (Haryana and Uttarakhand) to inform National Health Authority’s (NHA) p... more

Download (256)

View PDF (371)

WHO global report on trends in prevalence of tobacco use 2000-2025

World Health Organization WHO (2021) C_WHO

Progress in reducing tobacco use is a key indicator for measuring countries’ efforts to implement the WHO Framework Convention on Tobacco Control – target 3.a under the Sustainable Development Goals agenda. Countries have adopted this indicator to report progress also towards the tobacco reducti... more

Download (425)

View PDF (646)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (578)

View PDF (1197)

Generic risk assessment model for insecticide-treated nets, 2nd ed.

World Health Organization (WHO) (2018) C_WHO

Long-lasting insecticidal nets (LNs) constitute a core vector control intervention against malaria. A number of new LN products are under development and will require assessment of risks to humans. This document provides an updated generic model that can be used for the risk assessment of exposure t... more

Download (458)

View PDF (776)

Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus

World Health Organization WHO (2018) C_WHO

The new guidelines provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings. These guidelines update the recommendations for managing hyperglycaemia in the WHO Package of Essential NCD I... more

Download (349)

View PDF (347)

WHO recommendations on outpatient settings for induction of labour

World Health Organization WHO (2022) C_WHO

The primary audience for these recommendations includes health professionals who are responsible for developing national and local health-care guidelines and protocols and health workers involved in the provision of care to women and their newborns during pregnancy, labour and childbirth; this inclu... more

Download (484)

View PDF (536)

The impact of myopia and high myopia

World Health Organization (WHO) (2017) C_WHO

Report of the Joint World Health Organization–Brien Holden Vision Institute Global Scientific Meeting on Myopia | University of New South Wales, Sydney, Australia 16–18 March 2015

Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease recommended

Ten Immediate WASH Actions in Healthcare Facilities for COVID-19 Response recommended

Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease
recommended

Ten Immediate WASH Actions in Healthcare Facilities for COVID-19 Response
recommended